Previous studies demonstrated that SHP1 was generally recognized as a key modulator of insulin resistance and glucose metabolism in the liver, which participated in the pathogenesis of NAFLD as a negative regulator [18, 19]. The gene discussed is PTPN6; the disease is metabolic dysfunction-associated steatotic liver disease.